Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C

@article{Askarieh2010SystemicAI,
  title={Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C},
  author={Galia Askarieh and {\AA}sa Alsi{\"o} and Paolo Pugnale and Francesco Negro and Carlo Ferrari and Avidan U. Neumann and Jean Michel Pawlotsky and Solko W. Schalm and Stefan Zeuzem and Gunnar Norkrans and Johan Westin and Jonas S{\"o}derholm and Kristoffer Hellstrand and Martin Lagging},
  journal={Hepatology},
  year={2010},
  volume={51}
}
High systemic levels of interferon‐gamma‐inducible protein 10 kDa (IP‐10) at onset of combination therapy for chronic hepatitis C virus (HCV) infection predict poor outcome, but details regarding the impact of IP‐10 on the reduction of HCV RNA during therapy remain unclear. In the present study, we correlated pretreatment levels of IP‐10 in liver biopsies (n = 73) and plasma (n = 265) with HCV RNA throughout therapy within a phase III treatment trial (DITTO‐HCV). Low levels of plasma or… Expand
Plasma interferon‐gamma‐inducible protein‐10 (IP‐10) levels during acute hepatitis C virus infection
TLDR
High IP‐10 levels at acute HCV detection were associated with failure to spontaneously clear HCV, and patients with acuteHCV and high baseline IP‐ 10 levels, particularly >380 pg/mL, should be considered for early therapeutic intervention, and those with low levels should defer therapy for potential spontaneous clearance. Expand
Quantitation of pretreatment serum interferon‐γ–inducible protein‐10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response
TLDR
When IL28B genotype is combined with pretreatment serum IP‐10 measurement, the predictive value for discrimination between SVR and nonresponse is significantly improved, especially in non‐CC genotypes. Expand
Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection
TLDR
Baseline IP-10 levels are associated with early viral kinetics but not ultimate treatment outcome in acute HCV infection, given previous data showing that patients with high baseline IP- 10 are unlikely to spontaneously clear acute HCv infection, they should be prioritized for early antiviral therapy. Expand
IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV
TLDR
Investigating the utility of baseline plasma interferon-gamma inducible protein-10 levels in human immunodeficiency virus (HIV)–hepatitis C virus (HCV) co-infected patients concluded that baseline IP-10 <150 pg/ml is predictive of a favourable viral response to HCV therapy in HIV–HCV co- infected patients, and may thus be useful in encouraging such difficult-to-treat patients to initiate therapy. Expand
IP-10 in chronic hepatitis C patients treated with high-dose interferon.
TLDR
In patients treated with high induction dose interferon, IP-10 levels at any time point were not predictive for SVR, suggesting that, in this cohort, for prediction of SVR the added value of IP- 10 to IL28B genotype and early viral kinetics is limited. Expand
Relationship of interferon-&ggr;-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4
TLDR
The baseline IP-10 level is significantly lower in responders among HCV genotype-4d patients as compared with 4a patients as well as among responders among patients undergoing peginterferon/2a/ribavirin therapy. Expand
Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection
TLDR
Changes in IP‐10 levels mirror HCV RNA, suggesting thatIP‐10 is an indicator of innate immune viral recognition, suggesting differential immune activation in those who respond to SOF/RBV therapy and a potential role in predicting treatment responses. Expand
Impact of Soluble CD 26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection
Background: Interferon and ribavirin therapy for chronic hepatitis C virus (HCV) infection yields sustained virological response (SVR) rates of 50–80%. Several factors such as non-1 genotype,Expand
Association of interferon-γ inducible protein-10 pretreatment level and sustained virological response in HCV-positive Egyptian patients.
TLDR
Low pretreatment serum IP-10 is a favorable predictive of response to antiviral HCV therapy in Egyptian patients, particularly in patients who achieved SVR. Expand
Association of interferon-γ-induced protein-10 serum levels with virological responses to PEG-interferon-based therapy in hepatitis C virus genotype 1 or 2 chronically infected Chinese patients
TLDR
This study indicated that higher IP-10 serum levels were associated with HCV genotype 1 CHC Chinese patients and were both predictive of SVR and improved predictive performances of IL28B genotype and RVR for SVR. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
TLDR
Baseline IP-10 levels are predictive of the response to HCV treatment, and these levels decreased 6 weeks into treatment and remained low in patients with an SVR, but rebounded in patients who had detectable HCV RNA after the completion of treatment. Expand
IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection
TLDR
Pretreatment IP‐10 levels predict RVR and SVR in patients infected with HCV genotype 1, even in those with higher BMI and viral load, and may prove helpful in decision‐making regarding pharmaceutical intervention. Expand
First phase viral kinetic parameters and prediction of response to interferon alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C.
TLDR
Parameters of HCV kinetics 24h after the start of therapy are useful for the early prediction of outcome in response to IFN alpha-2b/ribavirin combination therapy in patients with chronic hepatitis C. Expand
Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment.
TLDR
The measurement of HCV load as early as 2 days after the start of pegylated interferon and ribavirin is a useful tool for the prediction of treatment outcome in individual patients and should be used in clinical practice. Expand
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.
TLDR
Findings show that infection with hepatitis C virus is highly dynamic and that early monitoring of viral load can help guide therapy, with blocking efficacies of 81, 95, and 96% for daily doses of 5, 10, and 15 million international units, respectively. Expand
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
TLDR
Findings show that infection with hepatitis C virus is highly dynamic and that early monitoring of viral load can help guide therapy, with blocking efficacies of 81, 95, and 96% for daily doses of 5, 10, and 15 million international units, respectively. Expand
Interferon signaling and treatment outcome in chronic hepatitis C
TLDR
The concept that activation of the endogenous IFN system in CHC not only is ineffective in clearing the infection but also may impede the response to therapy, most likely by inducing a refractory state of the IFN signaling pathway, is supported. Expand
First phase hepatitis c viral kinetics in previous nonresponders patients
TLDR
The log effectiveness of interferon was lower in nonresponders compared with treatment naive patients and the difference in antiviral effectiveness in previous nonresponder patients was overcome by higher interferons doses. Expand
Randomized comparison of 12 or 24 weeks of peginterferon α‐2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection
TLDR
Peginterferon/ribavirin treatment for 12 weeks in HCV genotype 2/3 infection is overall inferior to 24 weeks of treatment but may be useful in some patients with a rapid initial clearance of virus. Expand
Triphasic decline of hepatitis C virus RNA during antiviral therapy
TLDR
By including the proliferation of both uninfected and infected cells, a viral kinetic model can account for a triphasic HCV RNA decay and this generalized model can also explain the viral kinetics seen in flat partial responders. Expand
...
1
2
3
...